EPO blood pressure mystery: small study halted early
NCT ID NCT03810911
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 36 times
Summary
This study looked at why erythropoietin (EPO), a drug used to treat anemia, can raise blood pressure in people with chronic kidney disease. Researchers planned to enroll 160 participants but stopped early with only 27. The goal was to measure changes in blood pressure and blood vessel function over 12 weeks. Because it was terminated, the findings are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Richard L. Roudebush VA Medical Center, Indianapolis, IN
Indianapolis, Indiana, 46202-2884, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Darbepoetin (EPO)
What this could lead to
If successful, this could help doctors understand why EPO raises blood pressure, potentially leading to safer anemia treatments for kidney disease patients.
What could go wrong
The study was terminated early with only 27 out of 160 planned participants, so results are limited and may not be reliable. It was a small, early-phase study focused on understanding mechanisms, not testing a new treatment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.